常山药业：肝素钠注射液获坦桑药品注册证书

Core Viewpoint - Changshan Pharmaceutical (300255) has received a drug registration certificate for its Heparin Sodium Injection from the Tanzanian drug regulatory authority, which is primarily used for the prevention and treatment of thromboembolic diseases. The drug is valid until April 7, 2030, indicating a positive impact on the company's expansion into overseas markets [1]. Company Summary - The registration approval is expected to positively influence the company's efforts to expand its overseas market presence [1]. - Currently, the revenue from Heparin preparations in overseas sales constitutes a low percentage of the company's total operating revenue [1]. - The sales of the drug may be affected by various factors, including changes in overseas market policies, exchange rate fluctuations, and market competition [1].